Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.
About Electromed, Inc. (ELMD)
Electromed, Inc., headquartered in Minnesota, is a prominent player in the respiratory care industry, specializing in the development, manufacturing, and global distribution of innovative airway clearance therapy solutions. The company’s flagship product, the SmartVest® Airway Clearance System, utilizes advanced high-frequency chest wall oscillation (HFCWO) technology to provide a clinically proven, non-invasive alternative to traditional chest physiotherapy (CPT). This technology is designed to help patients with compromised pulmonary function clear excess mucus from their lungs, reducing the risk of infections and improving overall respiratory health.
Core Business and Products
At the heart of Electromed’s operations is the SmartVest System, which consists of a programmable air pulse generator, a wearable therapy garment, and a connecting hose. Together, these components deliver safe, comfortable, and effective airway clearance therapy. The system is particularly beneficial for individuals suffering from chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, atelectasis, and various neuromuscular diseases. By addressing the challenges of retained secretions, the SmartVest System enhances patients’ quality of life and reduces the frequency of hospitalizations related to respiratory complications.
Industry Position and Differentiation
Electromed operates in the highly specialized respiratory care market, where regulatory compliance, clinical efficacy, and patient comfort are paramount. The company distinguishes itself through its commitment to innovation, quality, and compassionate service. Its products are accredited by the Joint Commission and certified under ISO 13485:2003 and ISO 9001:2008 standards, underscoring its adherence to rigorous quality management systems. Additionally, the patented HFCWO technology provides a competitive edge by offering a more tolerable and effective solution compared to traditional CPT methods.
Business Model and Revenue Streams
Electromed generates revenue primarily through the direct sale of its SmartVest System and related accessories. The company also benefits from recurring revenue streams, which may include replacement parts, service agreements, and ongoing support for its devices. Its focus on patient-centric care and long-term relationships with healthcare providers further strengthens its market position.
Regulatory and Clinical Excellence
Operating within the medical device industry, Electromed is subject to stringent regulatory requirements. Its accreditation and ISO certifications reflect its dedication to maintaining high standards of safety and efficacy. The company’s products are backed by clinical research demonstrating their effectiveness in clearing mucus, reducing lung infections, and improving respiratory function. This evidence-based approach enhances its credibility among healthcare professionals and patients alike.
Market Significance
The respiratory care market continues to grow due to an aging population and the increasing prevalence of chronic respiratory conditions. Electromed’s innovative solutions address a critical need within this market, positioning the company as a key contributor to improving pulmonary health outcomes. By focusing on both technological advancement and patient well-being, Electromed has carved out a niche in the competitive landscape of airway clearance therapy.
Commitment to Patients and Healthcare Providers
Electromed’s mission extends beyond product development to include a strong emphasis on compassionate service and patient education. The company works closely with healthcare providers to ensure that its solutions are effectively integrated into treatment plans, empowering patients to manage their conditions more effectively. This holistic approach reinforces Electromed’s reputation as a trusted partner in respiratory care.
Electromed, Inc. (AMEX: ELMD) announced that it will release its financial results for the fiscal 2022 second quarter, ending December 31, 2021, on February 8, 2022, after the market closes. A conference call to discuss these results will be held at 5:00 p.m. ET on the same day, accessible via phone for domestic and international callers. The event can also be streamed live on the Investor Relations section of their website.
Electromed, a leader in airway clearance technologies, announced its participation in the Sidoti December Virtual Micro Cap Investor Conference on December 8-9, 2021. Key executives, including President Kathleen Skarvan and CFO Mike MacCourt, will present on December 8 at 2:30 p.m. Eastern Time and will be available for one-on-one meetings. Electromed is known for its SmartVest® Airway Clearance System, aimed at patients with compromised pulmonary function. The Company is based in New Prague, Minnesota, and has been operational since 1992.
Electromed, Inc. (NYSE American: ELMD) reported a record quarterly revenue of $10.0 million for Q1 FY 2022, reflecting a 25.0% increase year-over-year. Growth was driven by a 24.4% rise in home care revenue to $9.3 million and a 61.5% increase in institutional revenue. Gross profit margin improved to 77.0% despite rising costs. However, net income declined to $439,000 or $0.05 per diluted share. SG&A expenses rose to $6.8 million due to strategic investments. The company maintains $11.0 million in cash and continues to focus on product development and digital marketing strategies.
Electromed, Inc. (AMEX: ELMD) will release its fiscal 2022 Q1 financial results on November 9, 2021, after market close. A conference call will follow at 5:00 p.m. Eastern Time to discuss these results. Interested parties can join via phone or through a live webcast available on the company’s website. Electromed is known for its innovative airway clearance technologies, particularly the SmartVest Airway Clearance System, catering to patients with compromised pulmonary function.
Electromed, Inc. (NYSE: ELMD) has announced a cooperation agreement with Summers Value Partners, which holds 5.9% of its stock, leading to the nomination of two new independent directors, Kathy Tune and Joe Galatowitsch, for the upcoming Fiscal 2022 Annual Meeting. A new Finance and Strategy Committee will be formed to enhance value creation. Retiring board members Steve Craney and George Winn will leave their positions. The company highlighted its commitment to growth, showcasing a strategy that aims for double-digit revenue growth and profitability.
Electromed, Inc. (AMEX: ELMD) has announced that its President and CEO, Kathleen Skarvan, along with CFO Mike MacCourt, will participate in the 2021 Colliers Institutional Investor Conference on September 9, 2021. The conference will be held virtually, highlighting the company’s commitment to engaging with investors and stakeholders. Electromed specializes in airway clearance technologies, notably the SmartVest® Airway Clearance System, to assist patients with compromised pulmonary function. The company is based in New Prague, Minnesota, and has been operational since 1992.
Electromed reported strong Q4 FY 2021 results, with a net revenue increase of 37.7% to $9.5 million, driven by a 90.6% growth in institutional sales and 33.6% in home care. Despite revenue growth, operating income fell to $0.7 million from $1.3 million in Q4 FY 2020, affected by past government stimulus and increased SG&A expenses. For FY 2021, total revenue rose 10.1% to $35.8 million but net income declined to $2.4 million, or $0.27 per diluted share. Cash reserves were $11.9 million, bolstered by $3.1 million in operating cash flow.
Electromed (NYSE American: ELMD) announced that it will release its fiscal 2021 fourth quarter financial results on August 24, 2021, post-market close. A conference call will follow at 5:00 PM ET to discuss the results. Participants can join via domestic and international dialing or through a live webcast available on the Investor Relations section of their website. The company specializes in airway clearance therapy products, including the SmartVest Airway Clearance System, supporting patients with compromised pulmonary function.
Electromed (NYSE American: ELMD) announced that Summers Value Partners intends to nominate four candidates for election to the Board of Directors at the upcoming Fiscal 2022 Annual Meeting of Shareholders. The Board is currently engaged in discussions with Summers Value Partners to evaluate the nominees, focusing on shareholder interests. With insiders owning over 16% of Electromed's shares, their interests align closely with those of the shareholders. A proxy statement detailing the Board's recommendations will be filed with the SEC and distributed to eligible shareholders.
Electromed, Inc. (NYSE American: ELMD) announced preliminary Q4 FY 2021 financial results, projecting net revenue of $9.3 to $9.5 million, a 37% increase from $6.9 million in Q4 FY 2020. Operating income is expected to be between $0.5 and $0.7 million, down from $1.3 million the previous year, which included $0.9 million from government stimulus. The company reported $11.9 million in cash with no debt. Management indicated that a recent data security incident did not materially impact financial results for the quarter, affirming strong performance despite pandemic challenges.
FAQ
What is the current stock price of Electromed (ELMD)?
What is the market cap of Electromed (ELMD)?
What does Electromed, Inc. specialize in?
What is the SmartVest® Airway Clearance System?
Which conditions does Electromed’s SmartVest System treat?
How does Electromed differentiate itself in the respiratory care market?
What is high-frequency chest wall oscillation (HFCWO)?
What regulatory certifications does Electromed hold?
Who are Electromed’s primary customers?
What is the significance of Electromed’s ISO certifications?
